Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723040 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL9841873 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL17265729 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL5652692 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL14971389 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL15686649 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL4478966 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL10066970 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL3103625 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL14838314 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019506-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3083579-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20160108436-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | PROVIVI, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108436-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | PROVIVI, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| WO-2016042280-A1 | CONJUGATES OF AMINO ACID-PYRIDINE/PYRIDINIUM AND USES THEREOF AS BIOCIDAL AGENTS | Université de Nice Sophia Antipolis (FR) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015176020-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | PROVIVI, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-8877159-B2 | Phospholipid analogs as diapeutic agents and methods thereof | CELLECTAR, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140023587-A1 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF | CELLECTAR, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8535641-B2 | Phospholipid analogs as diapeutic* agents and methods thereof | CELLECTAR, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013071413-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED IODOTRIDECANE AND USE AS A REFERENCE STANDARD | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
| US-7700075-B2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | CELLECTAR, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2010026069-A2 | FIBERS, SURFACE STRUCTURES AND POLYMER FILMS HAVING A REVERSIBLE SHAPE MEMORY | BASF SE (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20070098633-A2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | CELLECTAR, LLC (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1265838-A1 | NOVEL FATTY ACID ANALOGOUS | Thia Medica AS (NO) | 2002-12-18 | — | — | EP | disclosed |
| US-6423698-B1 | ADMINISTERING INHIBITOR OF 17-BETA-HYDROXYSTEROID DEHYDROGENASE AND AT LEAST ONE OF AN INHIBITOR OF AROMATASE AND INHIBITOR OF 5-ALPHA-REDUCTASE | ENDORECHERCHE, INC. (CA) | 2002-07-23 | — | — | US | disclosed |
| WO-2001068582-A1 | NOVEL FATTY ACID ANALOGOUS | THIA MEDICA AS (NO) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108436-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | CYP2E1, ADH5, CYP1A2 | MEN1 4726/4885KMT2A 1584/4885ALDH1A1 155/4885 |
| US-20070098633-A2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | PHOSPHO1, APC, LPCAT3 | MEN1 304/4885KMT2A 661/4885ALDH1A1 3900/4885 |
| US-20140023587-A1 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF | PHOSPHO1, SGMS1, CDIPT | MEN1 962/4885KMT2A 3079/4885ALDH1A1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.